Joint Submission Alignment and Stakeholder Coordination Under REACH

Overview

Under EU REACH, registrants of the same substance are generally required to participate in joint submission frameworks in order to support data sharing, minimise unnecessary testing and maintain consistency across registration activities.

For complex bio-based substances and substances of unknown or variable composition, complex reaction products or biological materials (UVCBs), alignment with existing joint submissions may present significant technical and regulatory complexity.

Assessment of substance sameness requires consideration of:

• manufacturing process,
• compositional boundaries,
• analytical characterisation,
• and alignment with existing Substance Identity Profiles (SIPs).

For many complex substances, successful participation within joint registration frameworks depends upon demonstrating sufficient scientific and regulatory alignment across highly variable material profiles.

---

Core Challenge

The primary challenge was determining whether complex bio-based substances could be considered sufficiently similar to existing registered substances for participation within joint submission frameworks.

Key considerations included:

• variability arising from natural feedstocks and processing conditions
• limitations in full constituent identification
• interpretation of compositional ranges
• alignment with existing Substance Identity Profiles (SIPs)
• consistency between manufacturing process and proposed substance identity
• applicability of existing datasets across variable compositions
• and coordination across multiple registrants and stakeholders

For UVCB substances, small differences in:

• source material,
• process conditions,
• constituent distribution,
• or impurity profiles

may create significant implications for substance sameness assessment and access to existing joint registration structures.

---

Joint Submission Alignment Approach

Substance Sameness Assessment

Substances were assessed against existing registration frameworks to determine potential alignment with established Substance Identity Profiles.

This included evaluation of:

• compositional ranges
• manufacturing process descriptions
• analytical datasets
• constituent profiles
• and relevant regulatory identifiers

Assessment activities considered whether proposed substances could reasonably fall within accepted boundary compositions for existing registrations.

---

Substance Identity Profile (SIP) Evaluation

Existing SIPs were reviewed to assess:

• permitted compositional boundaries
• constituent interpretation
• process-derived identity considerations
• and broader substance sameness criteria

For complex bio-based substances, interpretation frequently required balancing:

• analytical variability,
• process consistency,
• and regulatory expectations relating to identity robustness.

---

Stakeholder Engagement and Lead Registrant Coordination

Engagement with lead registrants and existing submission groups supported evaluation of:

• substance alignment potential
• access to existing joint submissions
• data sharing considerations
• and broader participation requirements

This required coordination across:

• technical stakeholders
• regulatory representatives
• laboratories
• and commercial participants

to support alignment of scientific and regulatory interpretations.

---

Boundary Composition and Variability Management

Boundary composition assessment formed a critical component of joint submission evaluation.

This included:

• review of acceptable compositional variability
• assessment of constituent ranges
• evaluation of impurity profiles
• and consideration of long-term source consistency

For substances derived from variable natural materials, maintaining alignment within agreed compositional boundaries represented an ongoing regulatory consideration.

---

Data and Regulatory Consistency Review

Alignment activities also considered consistency between:

• existing endpoint datasets
• hazard classification
• intended uses
• and exposure considerations

This was particularly important where:

• evolving compositional understanding,
• analytical limitations,
• or process variation

could influence interpretation of existing registration coverage.

---

Outcome

• Substance sameness assessments completed against existing registration frameworks
• Alignment with Substance Identity Profiles evaluated
• Joint submission participation pathways assessed
• Boundary composition considerations established
• Stakeholder engagement conducted across relevant registrants and regulatory participants
• Data sharing and regulatory alignment activities supported
• Long-term consistency considerations incorporated into registration strategy
• Participation within joint submission structures supported where applicable

---

Key Consideration

For complex bio-based substances, participation within joint submission frameworks requires more than compositional similarity alone. Regulatory alignment depends upon maintaining consistency across manufacturing process, analytical interpretation, constituent variability and broader scientific justification throughout the registration lifecycle.